The transition from a blockbuster to personalised cancer therapy
CCBIO organized a special session with focus on the transition from a blockbuster to personalised cancer therapy at the S.Net conference recently held in Bergen.
The 8th S.Net conference
From the 12th to the 14th of October 2016, the Centre for the Study of the Sciences and the Humanities hosted the 8th S.Net conference, with a focus on the co-production and governance of new and emerging technologies. This theme was addressed from a variety of angles, ranging from public engagement to innovation politics and policies, safety and security, as well as narratives, imaginaries and visualisation of future technologies.
CCBIO special session
First, Alessandro Blassimme discussed socio-technical imaginaries of precision medicine, comprising two main components: materiality - that is the quantification of personal health data through devices such as watches or apps; and agency – that is the sharing and use of these personal health data for self-monitoring and changes towards more ‘healthy’ lifestyles. Alessandro argued that precision medicine thus contributes to creating digital selves.
Complex relationship between industry, public research and government
Then, Anne Blanchard addressed the partnerships between science, industry and government in the transition from a blockbuster cancer model to personalised medicine. Although necessary to take scientific discoveries to the patients’ bedside, Anne argued that these partnerships are complex, pose practical challenges, and may ‘co-produce’ unwanted outcomes such as an increased culture of medicalisation and new questions of social and global justice.
The patient's perspective
Caroline Engen finished the session by providing an ‘insider’s perspective on targeted therapy, the immense complexity of the biology of cancer, and the equally important challenges of validating cancer biomarkers for personalised medicine. Caroline also discussed some of the problematic aspects of personalised medicine, including the focus on trying to find a treatment for patients at a terminal stage rather than palliative care, and the right not to know your genetic traits.
From Reflection to Action
Caroline Engen noted that her presentation amounts to an instance of "Responsible Research and Innovation" - RRI - a key concept in this year's S.Net meeting. Indeed, the same may be said about the entire ethics/social science/economics component of CCBIO. RRI prescribes anticipation of and reflection upon future implications of research but also action. Since 2015, CCBIO researchers, notably Blanchard, have discussed the changing political economy of personalised cancer therapy in a series of seminars and conferences.
"Action" will now include written dissemination of the analyses that have been made but also further work to integrate them into the governance and the practices of CCBIO itself. This quite rare and distinctive feature of CCBIO was widely acknowledged in the discussion of the S.Net CCIO session, which gathered a broad group of scholars and scientists, including some of CCBIO's own junior scientists.
Also see related content below.